Regimen Reference Order – LEUK – blinatumomab

ARIA: LEUK - [blinatumomab]

Planned Course: Induction (Cycles 1, 2 and 3) and Consolidation (Cycles 4 and 5): 28 days of treatment (continuous infusion), followed by 14 days with no therapy (1 cycle = 42 days)

Note: Initial CCMB Outpatient blinatumomab infusion bag change is variable depending on when patient is discharged from hospital.

Treatment appointments for blinatumomab must be scheduled at 1130H to ensure coordination between treatment room and Pharmacy. blinatumomab bags are changed at CCMB at 1130H regardless of any residual volume remaining in the bag (as each bag is prepared with overfill).

This RRO outlines initial CCMB Outpatient blinatumomab infusion bag on Day 10 of Cycle 1 and on Day 5 of Cycle 2. Refer to Appendix A (page 7) and Appendix B (page 8) for variations to dose and pump infusion times if patient has a different start day.

See regimen Dosing Schemas (page 6)

Indication for Use: Acute Lymphoblastic Leukemia

Alert: Protocol is restricted to adult patients greater than or equal to 45 kg.

For patients with Minimal Residual Disease (MRD positive), refer to RRO LEUK – blinatumomab (MRD positive)

CVAD: Required (Ambulatory Pump) – PICC Preferred

Proceed with treatment if:

- AST/ALT is less than 5 times the upper limit of normal
- Total bilirubin is less than 3 times the upper limit of normal
- Creatinine Clearance is greater than 30 mL/minute

Proceed regardless of platelets or ANC

Contact Leukemia/BMT (L/BMT) Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

	Pre-treatm	ent Requirements											
Drug	Drug Dose CCMB Administration Guideline												
	No	t Applicable											



Drug	Dose	CCMB Administration Guideline
-	Dose	
Cycle 1 Induction		
Days 1 to 9		
	•	itment for the first 9 days of Cycle 1. Follow inpatient orders via ambulatory infusion starting at 1130H
Days 10, 14, 18 and 22		
blinatumomab Day 26	112 mcg (28 mcg/day)	 IV in normal saline continuously <u>over 96 hours</u> by ambulatory infusion device to start at 1130H <i>CADD SOLIS VIP settings:</i> <i>Infusion rate = 2.5 mL/hour</i> <i>Reservoir Volume = 240 mL</i> <i>Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter</i> *Nursing Alert: IV tubing is primed with blinatumomab *Nursing Alert: Change bag exactly every 96 hours. Discard remainder of solution in IV bag and IV line at every bag change *Nursing Alert: Withdraw 2 mL of blood prior to flushing as a bolus of blinatumomab can be harmful to patient <i>Note</i>: If patient requires an initial CCMB Outpatient blinatumomab bag change on a different start day (i.e. not on Day 10, 14, 18 or 22), patient will receive a one-time only initial 48-hour infusion pump, then switch to every 96-hour bag changes. Refer to Appendix A
blinatumomab	84 mcg (28 mcg/day)	 IV in normal saline continuously <u>over 72 hours</u> by ambulatory infusion device to start at 1130H <i>CADD SOLIS VIP settings:</i> <i>Infusion rate = 3.3 mL/hour</i> <i>Reservoir Volume = 240 mL</i> <i>Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter</i> *Nursing Alert: IV tubing is primed with blinatumomab *Nursing Alert: Change bag exactly every 96 hours. Discard remainder of solution in IV bag and IV line at every bag change and on Day 29 at 1130H *Nursing Alert: Withdraw 2 mL of blood prior to flushing as a bolus of blinatumomab can be harmful to patient *Alert: Dose in bag and infusion rate for Cycle 1, Day 26 is different from all other days of cycle
Cycle 2 Induction	· ·	
Days 1 to 4		

Days 5, 9, 13, 17, 21	and 25	
blinatumomab	112 mcg (28 mcg/day)	IV in normal saline continuously <u>over 96 hours</u> by ambulatory infusion device to start at 1130H
		CADD SOLIS VIP settings:
		Infusion rate = 2.5 mL/hour
		Reservoir Volume = 240 mL
		Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter
		*Nursing Alert: IV tubing is primed with blinatumomab
		*Nursing Alert: Change bag exactly every 96 hours. Discard remainder of solution in IV bag and IV line at every bag change and on Day 29 at 1130H
		*Nursing Alert: Withdraw 2 mL of blood prior to flushing as a bolus of blinatumomab can be harmful to patient
		<u>Note</u> : If patient requires an initial CCMB Outpatient blinatumomab bag change on a different start day (i.e. not on Day 5, 9, 13, 17, 21 or 25), patient will receive a one-time only initial 48-hour infusion pump, then switch to every 96-hour bag changes. Refer to Appendix B
Cycle 3 Induction an	d Cycles 4 and 5 Conso	lidation
Day 1	•	
cetirizine	10 mg	Orally 30 minutes prior to blinatumomab
acetaminophen	650 mg	Orally 30 minutes prior to blinatumomab
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes <u>1 hour</u> prior to blinatumomab
		*Nursing Alert: blinatumomab starts 1 hour after completion of dexamethasone infusion
Wait 1 hour after com	pletion of IV pre-medicat	tion(s) before starting blinatumomab
blinatumomab	112 mcg (28 mcg/day)	IV in normal saline continuously <u>over 96 hours</u> by ambulatory infusion device to start at 1130H
		CADD SOLIS VIP settings:
		Infusion rate = 2.5 mL/hour
		Reservoir Volume = 240 mL
		Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter
		*Nursing Alert: IV tubing is primed with blinatumomab
		*Nursing Alert: Withdraw 2 mL of blood prior to flushing as a bolus of blinatumomab can be harmful to patient
Days 5, 9, 13, 17, 21	and 25	
blinatumomab	112 mcg	IV in normal saline continuously over 96 hours by ambulatory
	(28 mcg/day)	infusion device to start at 1130H
		CADD SOLIS VIP settings:
		Infusion rate = 2.5 mL/hour
		Reservoir Volume = 240 mL



•	n.		T
A	ועו	л	
			•••

Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter
*Nursing Alert: IV tubing is primed with blinatumomab
*Nursing Alert: Change bag exactly every 96 hours. Discard remainder of solution in IV bag and IV line at every bag change and on Day 29 at 1130H
*Nursing Alert: Withdraw 2 mL of blood prior to flushing as a bolus of blinatumomab can be harmful to patient

Do NOT flush line when drug is running. This may result in an unintended bolus of blinatumomab. If accessing lumen, withdraw 2 mL of blood (containing drug) first, and then flush.

In the event of an infusion-related hypersensitivity reaction, contact Leukemia/BMT Physician on call

REQUIRED MONITORING

Throughout therapy

- Monitor for signs and symptoms of cytokine release syndrome (CRS). Serious adverse events that may be associated with CRS include: pyrexia, headache, nausea, asthenia, hypotension, and elevations in serum aminotransferases and bilirubin
- Monitor for signs and symptoms of neurotoxicity. Symptoms may include: trembling, disturbance or loss of
 movement of parts of the body, speech or coordination disorders, apraxia, dizziness, confusion, disorientation,
 reversible seizures, encephalopathy, somnolence and agitation
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O2 saturation) as clinically indicated

Cycle 1

Each bag change

• CBC with differential, serum creatinine, urea, electrolytes including phosphate and calcium, AST, ALT, Alkaline phosphatase, LDH, GGT, total bilirubin, uric acid and albumin as per Physician Orders

Twice weekly

Lipase

Cycle 2 and Onwards

Weekly

• CBC with differential, serum creatinine, urea, electrolytes including phosphate and calcium, AST, ALT, Alkaline phosphatase, LDH, GGT, total bilirubin, uric acid and albumin as per Physician Orders

Twice weekly

• Lipase



	Recommended	Support Medications													
Drug	Drug Dose CCMB Administration Guideline														
	Ν	one required													

DISCHARGE INSTRUCTIONS

 Advise patient to contact L/BMT Physician on call if they encounter problems with ambulatory infusion pump after hours

ADDITIONAL INFORMATION

- This protocol only applies to adult patients greater than or equal to 45 kg
- Site restrictions are in place for blinatumomab. blinatumomab must be administered at CCMB MacCharles in Winnipeg



ADULT

Dosing Schema - Cycle 1

Initial CCMB Outpatient blinatumomab infusion bag change on Day 10

Day	10*	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30 to 42
blinatumomab																				D/C**	
CCMB bag change																				D/C**	
Total dose per bag (mcg)		11	.2			11	12			11	12			11	12			84			
Infusion rate (mL/hr)		2.	5			2	.5			2.	.5			2.	.5			3.3			

*48-hour bag dispensed by HSC on Day 8 will be disconnected at CCMB on Day 10 and replaced with a 96-hour bag

**blinatumomab infusion pump is disconnected on Day 29 (D/C = Disconnect)

Key:

Indicates that blinatumomab will be administered on this day

Indicates blinatumomab bag change on this day

Dosing Schema - Cycle 2

Initial CCMB Outpatient blinatumomab infusion bag change on Day 5

Day	5*	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30 to 42
blinatumomab																									D/C**	
CCMB bag change																									D/C**	
Total dose per bag (mcg)		11	12			11	12			11	12			11	12			1:	12			11	12			
Infusion rate (mL/hr)		2.	.5			2.	.5			2.	5			2	.5			2	.5			2.	.5			

*48-hour bag dispensed by HSC on Day 3 will be disconnected at CCMB on Day 5 and replaced with a 96-hour bag **blinatumomab infusion pump is disconnected on Day 29 (D/C = Disconnect)

Key:



Indicates that blinatumomab will be administered on this day

Indicates blinatumomab bag change on this day



APPENDIX A – CYCLE 1

Cycle 1 – Variations to Initial CCMB Outpatient blinatumomab Infusion Bag Change

Day of initial CCMB Outpatient blinatumomab infusion bag change	Dose	CCMB Administration Guidelines
Day 12, 16, 20 or 24	56 mcg (28 mcg/day)	IV in normal saline continuously <u>over 48 hours</u> by ambulatory infusion device to start at 1130H <i>CADD SOLIS VIP settings:</i> <i>Infusion rate = 5 mL/hour</i> <i>Reservoir Volume = 240 mL</i>
for the initial dose only, then patien	nt will switch to eve inatumomab 48 hr	n Day 12, 16, 20 or 24, then a 48-hour bag will be ordered ry 96-hour bag changes as outlined in RRO in the "Leukemia" folder is to be used to order the 48-hour

Example: Initial CCMB Outpatient blinatumomab infusion bag change on Day 12

	Day	12*	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30 to 42
blinatumomab																			D/C**	
CCMB bag change																			D/C**	
Total dose per bag (mcg)		50	6		11	12			11	12			11	12			84			
Infusion rate (mL/hr)		5	5		2.	.5			2	.5			2	.5			3.3			

*48-hour bag dispensed by HSC on Day 10 will be disconnected at CCMB on Day 12 and replaced with a 48-hour bag **blinatumomab infusion pump is disconnected on Day 29 (D/C = Disconnect)

Key:

Indicates that blinatumomab will be administered on this day

Indicates blinatumomab bag change on this day

Please refer to CCMB Formulary for Criteria for Use



APPENDIX B – CYCLE 2

Day of initial CCMB Outpatient blinatumomab infusion bag change	Dose	CCMB Administration Guidelines
Day 3, 7, 11, 15, 19, 23 or 27*	56 mcg (28 mcg/day)	IV in normal saline continuously <u>over 48 hours</u> by ambulatory infusion device to start at 1130H <i>CADD SOLIS VIP settings:</i> <i>Infusion rate = 5 mL/hour</i> <i>Reservoir Volume = 240 mL</i>
*Day 27: One-time infusion bag to compl Additional Information (Cycle 2):	ete Cycle 2	
ordered for the initial dose only,	then patient will sw	on Day 3, 7, 11, 15, 19, 23 or 27, then a 48-hour bag will be itch to every 96-hour bag changes as outlined in RRO
	inatumomab 48 hr i	CCMB on Day 27, then a 48-hour bag will complete Cycle 2 n the "Leukemia" folder is to be used to order the 48-hour

Example: Initial CCMB Outpatient blinatumomab infusion bag change on Day 7

Day	7*	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30 to 42
blinatumomab																							D/C**	
CCMB bag change																							D/C**	
Total dose per bag (mcg)	5	6		11	12			11	2			11	2			11	.2			11	12			
Infusion rate (mL/hr)	Ξ,	5		2.	.5			2.	5			2.	5			2.	5			2.	.5			

*48-hour bag dispensed by HSC on Day 5 will be disconnected at CCMB on Day 7 and replaced with a 48-hour bag

**blinatumomab infusion pump is disconnected on Day 29 (D/C = Disconnect)

Key:

Indicates that blinatumomab will be administered on this day

Indicates blinatumomab bag change on this day

Please refer to CCMB Formulary for Criteria for Use

